The Bid & Ask

Quotations, Dispatches, and the Daily Tape

Thursday, August 13, 2026

Subject of the day

QDEL

Concerning the House

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.

United States · www.quidelortho.com

The Long Run

FY 2022–2025 · 4 years

LineLatestCAGRTrend
Revenue$3.00B+21.7%
Operating income$139.10M-63.8%
Net income-$10.10M-17.7%
Cash from ops$105.20M-49.3%
Quotation

$15.09

+0.26 (+1.8%)

52w hi$35.38
52w lo$9.96
Vol1.45M
As ofAug 13
The Verdict

Hold

Our score -0.31

Short-0.25
Medium-0.22
Long-0.59

computed 2026-08-13

By the Numbers

QuidelOrtho Corporation

Healthcare · Medical Devices

Market cap$1.03B
Enterprise value$3.97B
Trailing P/E
Forward P/E10.28x
EV / EBITDA8.19x
P / S (ttm)0.39x
Profit margin-39.2%
Return on equity-45.9%
Revenue growth+2.8%
Earnings growth
Debt / equity173.28
Risk Metrics
Beta vs SPX1.78
Corr SPX0.37
Annual vol78.3%
Annual ret-20.2%
Sharpe-0.26
Max DD-79.1%

Window: 504 trading days (504 obs)

Layer Breakdown
LayerRawContribution
Fundamental-0.11
Sector+0.12
Technical-0.15
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-08-13

Recent Sessions
DateOpenHighLowCloseVol
Aug 13$14.83$15.52$14.34$15.091.45M
Aug 12$13.78$14.93$13.72$14.831.95M
Aug 11$13.59$14.24$13.28$13.991.50M
Aug 10$12.11$13.84$12.07$13.752.81M
Aug 7$12.67$13.22$11.41$12.294.89M